Search Results - "Necchi, A."

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B.P., Ravaud, A., Shariat, S.F., Szabados, B., van der Heijden, M.S., Gillessen, S.

“…•This ESMO Clinical Practice Guideline provides key recommendations for diagnosis, staging and management of bladder cancer.•Recommendations for personalised…”
Get full text

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up by Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.

“…Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a…”
Get full text

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study by Necchi, A., Joseph, R.W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J.L., Petrylak, D.P., Derleth, C.L., Tayama, D., Zhu, Q., Ding, B., Kaiser, C., Rosenberg, J.E.

“…Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase…”
Get full text

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis by Raggi, D., Miceli, R., Sonpavde, G., Giannatempo, P., Mariani, L., Galsky, M.D., Bellmunt, J., Necchi, A.

“…The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial…”
Get full text

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up by Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., Fizazi, K., Fosså, S., Germa-Lluch, J.R., Giannatempo, P., Gietema, J.A., Gillessen, S., Haugnes, H.S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M.A.S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondruš, D., Papachristofilou, A., Powles, T., Sohaib, A., Ståhl, O., Tandstad, T., Toner, G., Horwich, A.

“…The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3–5 November 2016 in Paris, France. The conference…”
Get full text

Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study by Bandini, M., Gibb, E.A., Gallina, A., Raggi, D., Marandino, L., Bianchi, M., Ross, J.S., Colecchia, M., Gandaglia, G., Fossati, N., Pederzoli, F., Lucianò, R., Colombo, R., Salonia, A., Briganti, A., Montorsi, F., Necchi, A.

“…Initial studies of preoperative checkpoint inhibition before radical cystectomy (RC) have shown promising pathologic complete responses. We aimed to analyze…”
Get full text

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) by Grivas, P, Loriot, Y, Morales-Barrera, R, Teo, M Y, Zakharia, Y, Feyerabend, S, Vogelzang, N J, Grande, E, Adra, N, Alva, A, Necchi, A, Rodriguez-Vida, A, Gupta, S, Josephs, D H, Srinivas, S, Wride, K, Thomas, D, Simmons, A, Loehr, A, Dusek, R L, Nepert, D, Chowdhury, S

“…ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic…”
Get full text

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up by Balar, A.V., Castellano, D.E., Grivas, P., Vaughn, D.J., Powles, T., Vuky, J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Necchi, A., Petrylak, D.P., Plimack, E.R., Xu, J.Z., Imai, K., Moreno, B.H., Bellmunt, J., de Wit, R., O’Donnell, P.H.

“…Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response…”
Get full text

Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study by Giannatempo, P., Raggi, D., Marandino, L., Bandini, M., Farè, E., Calareso, G., Colecchia, M., Gallina, A., Ross, J.S., Alessi, A., Briganti, A., Montorsi, F., Madison, R., Necchi, A.

“…Pembrolizumab is a new standard of care for patients with platinum-treated, metastatic urothelial carcinoma (UC). Nab-paclitaxel is active in advanced UC. In…”
Get full text

Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes by Giannatempo, P., Greco, T., Mariani, L., Nicolai, N., Tana, S., Farè, E., Raggi, D., Piva, L., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Avuzzi, B., Maffezzini, M., Landoni, G., De Braud, F., Gianni, A.M., Sonpavde, G., Salvioni, R., Necchi, A.

“…After a comprehensive review and meta-analysis, radiotherapy and chemotherapy appeared to be similarly effective overall in clinical stage (CS) IIA and IIB…”
Get full text

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201 by Necchi, A, Pouessel, D, Leibowitz, R, Gupta, S, Fléchon, A, García-Donas, J, Bilen, M A, Debruyne, P R, Milowsky, M I, Friedlander, T, Maio, M, Gilmartin, A, Li, X, Veronese, M L, Loriot, Y

“…Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of…”
Get more information

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) by Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.-N., Kumar Pal, S., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Necchi, A., Sternberg, C.N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Bellmunt, J., Galsky, M.D.

“…Cisplatin-based combination chemotherapy is the standard treatment of advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin…”
Get full text

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy by Lorch, Anja, Beyer, Jörg, Bascoul-Mollevi, Caroline, Kramar, Andrew, Einhorn, Lawrence H, Necchi, Andrea, Massard, Christophe, De Giorgi, Ugo, Fléchon, Aude, Margolin, Kim A, Lotz, Jean-Pierre, Germa Lluch, Jose Ramon, Powles, Thomas, Kollmannsberger, Christian K

“…To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Data from…”
Get full text

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial by Necchi, A., Lo Vullo, S., Giannatempo, P., Raggi, D., Calareso, G., Togliardi, E., Crippa, F., Pennati, M., Zaffaroni, N., Perrone, F., Busico, A., Colecchia, M., Nicolai, N., Mariani, L., Salvioni, R.

“…Therapeutic options for patients with chemoresistant germ cell tumors (GCTs) are limited. Pazopanib is a selective tyrosine kinase inhibitor with distinct…”
Get full text

Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression by Rosenberg, J., Necchi, A., Sweis, R.F., Nakajima, K., Lu, C., Nogai, H.

Get full text

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) by De Santis, M., Wiechno, P.J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W.C., Retz, M.M., Vaissière, N., Culine, S.

“…There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the…”
Get full text

Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study by Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Fléchon, A., Daugaard, G., Fedyanin, M., Faré, E., Bokemeyer, C.

“…Bone metastases (BM) are rare in germ cell tumor (GCT) patients. Systematic data on risk factors, treatment and outcome are largely lacking. A database created…”
Get full text

HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study by Ghelani, G H, Zerdan, M Bou, Jacob, J, Spiess, P E, Li, R, Necchi, A, Grivas, P, Kamat, A, Danziger, N, Lin, D, Huang, R, Decker, B, Sokol, E S, Cheng, L, Pavlick, D, Ross, J S, Bratslavsky, G, Basnet, A

“…Advanced bladder squamous cell carcinoma (aBSCC) is an uncommon form of urinary bladder malignancy when compared with the much higher urothelial carcinoma…”
Get full text

A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer by Hurvitz, S.A., Galsky, M.D., Shahidi, J., Zhang, G., Raza, S., Necchi, A.

Get full text

A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations by Necchi, A., Pérez-Gracia, J.L., Loriot, Y., Witjes, W., Montorsi, F., Bjartell, A., Shariat, S.F.

“…Background: After neoadjuvant chemotherapy (NAC), about 20% of pts with muscle-invasive UC are found to have advanced pT-stage or lymph node involvement and…”
Get full text